Source: tvnz.co.nz
The nearly 50,000 New Zealanders taking the anti-depressant Aropax will soon be offered a new subsidised drug to replace it.
Funding for Aropax is being phased out in favour of the clinically identical Loxamine, which will be available from April.
Pharmac says because Loxamine is being sold at a lower price by its makers, it will free-up an extra $45 million to spend on other drugs.
Nothing to do with the fact that Aropax causes severe side effects during withdrawal or the fact that there are and have been numerous class action lawsuits against GlaxoSmithKline regarding this particular drug?
Zantac Lawsuit
Researching drug company and regulatory malfeasance for over 16 years
Humanist, humorist
Please contact me if you would like a guest post considered for publication on my blog.
No comments: